Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole

Clinical Pharmacokinetics

Volumn 41, Issue SUPPL. 1, 2002, Pages 37-44

  Banfield, C ^a   Herron, J ^b   Keung, A ^a   Padhi, D ^a   Affrime, M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Research Solutions LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYDESLORATADINE; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DESLORATADINE; DRUG METABOLITE; KETOCONAZOLE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FEMALE; HEADACHE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PR INTERVAL; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; SYNCOPE; VERTIGO;

EID: 0036074083     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241001-00006     Document Type: Article

References (17)

1. Treating allergic rhinitis with second-generation antihistamines
2. Arrhythmogenic mechanisms of non-sedating antihistamines
3. Cardiac ion channels and antihistamines: Possible mechanisms of cardiotoxicity
4. 1 receptor blocker cetirizine compared with other second-generation antihistamines
5. Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: Possible mechanism for terfenadine-associated cardiotoxicity
6. Torsades de pointes after treatment with terfenadine and ketoconazole
7. Combined use of astemizole and ketoconazole resulting in torsade de pointes
8. Blockade of HERG and Kv1.5 by ketoconazole
9. 1 receptor antagonist. 1st communication: Receptor selectivity, antihistaminic activity, and antiallergenic effects
10. Efficacy and tolerability of once-daily 5mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis. Assessment during the spring and fall allergy seasons
11. 1 receptor antagonist. 2nd communication: Lack of central nervous system and cardiovascular effects
12. A pharmacokinetic profile of desloratadine in healthy adults, including elderly
13. Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine
14. Cardiovascular profile of loratadine
15. Lack of clinically relevant interaction between desloratadine and erythromycin